Rewriting Cellular Metabolism
to Target Senescence
CorTech envisions a future where senescent and diseased cells can be precisely identified and selectively eliminated—while healthy cells are spared. By harnessing cellular metabolism, mitochondrial state, and membrane potential, our platform aims to guide senolytic therapies to the cells that need them most. Combining metabolic switching with cellular reprogramming, CorTech is working toward more selective treatments with reduced off-target effects and the potential to address cancer, age-related disease, and degenerative conditions.
This scientifically validated and differentiated platform creates evidence-based opportunities across pharmaceuticals, nutraceuticals, dietary supplements, functional wellness, healthy aging, and the emerging cellular beauty market—serving the expanding global healthcare, wellness, beauty, and life-science sectors.
HOW IT WORKS
Targeting Mitochondrial Voltage
to Precisely Eliminate Cancer Cells
and Prevent Relapse
OUR MISSION & VISION
We seek strategic partners to evaluate, license, and co-develop Cor-Technology, rewiring cellular metabolisms to target senescence platform. Protected by a provisional patent application and supported by an expanding IP strategy, the platform enables customized research and product-development opportunities across pharmaceutical, wellness, healthy-aging, and cellular-beauty markets.
